Your browser doesn't support javascript.
loading
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors.
Manglaviti, Sara; Bini, Marta; Apollonio, Giulia; Zecca, Ernesto; Galli, Giulia; Sangaletti, Sabina; Labianca, Alice; Sottotetti, Elisa; Brambilla, Marta; Occhipinti, Mario; Proto, Claudia; Prelaj, Arsela; Signorelli, Diego; De Toma, Alessandro; Viscardi, Giuseppe; Beninato, Teresa; Mazzeo, Laura; Bottiglieri, Achille; Leporati, Rita; Fotia, Giuseppe; Ganzinelli, Monica; Portararo, Paola; Garassino, Marina Chiara; de Braud, Filippo G M; Lo Russo, Giuseppe; Torri, Valter; Ferrara, Roberto.
Affiliation
  • Manglaviti S; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Bini M; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Apollonio G; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Zecca E; Palliative Care, Pain Therapy and Rehabilitation Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Galli G; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Sangaletti S; Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Labianca A; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Sottotetti E; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Brambilla M; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Occhipinti M; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Proto C; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Prelaj A; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Signorelli D; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • De Toma A; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Viscardi G; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Precision Medicine Department, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy.
  • Beninato T; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Mazzeo L; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Bottiglieri A; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Leporati R; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Fotia G; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Ganzinelli M; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Portararo P; Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Garassino MC; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Division of the Biological Sciences, University of Chicago, Chicago, IL, USA.
  • de Braud FGM; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Oncology and Hemato-oncology Department, University of Milan, Milan, Italy.
  • Lo Russo G; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Torri V; Methodology for Clinical Research Laboratory, Istituto di Ricerche Farmacologiche Mario Negri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
  • Ferrara R; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy; Medical Oncology, IRCCS Ospedale San Raffaele
Lung Cancer ; 186: 107417, 2023 12.
Article in En | MEDLINE | ID: mdl-37918061
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bone Neoplasms / Carcinoma, Non-Small-Cell Lung / Antineoplastic Agents, Immunological / Lung Neoplasms / Antineoplastic Agents Limits: Humans Language: En Journal: Lung Cancer Journal subject: NEOPLASIAS Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bone Neoplasms / Carcinoma, Non-Small-Cell Lung / Antineoplastic Agents, Immunological / Lung Neoplasms / Antineoplastic Agents Limits: Humans Language: En Journal: Lung Cancer Journal subject: NEOPLASIAS Year: 2023 Document type: Article Affiliation country: Country of publication: